SEC Form 4 · accession 0001140361-15-042172
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Nov 16, 2015
Accepted (ET)
Nov 18, 2015 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 16, 2015 | M | 20,000 | $39.06 | A | 48,229 | D | |
| Common StockF1,F2 | Nov 16, 2015 | S | 20,000 | $104.2959 | D | 28,229 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF1,F4,F3 | $39.06 | Nov 16, 2015 | M | 20,000 | D | Nov 29, 2012 | May 28, 2022 | Common Stock | 20,000 | 19,500 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on September 14, 2015.
- F2The price in column 4 is a weighted average price. The price actually received ranged from $102.98 to $107.57. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3Original option grant vests 6/48ths on November 29, 2012, and 1/48th on the 29th day of every month thereafter.
- F4Reflects the number of stocks options that remain outstanding from this specific stock option grant following the reported transaction.